Invokana dosing explained down below. This is not official statement, for more information; please keep reading until end and go for Prescription.
Invokana 100 mg is that the only SGLT2i approved for patients with an eGFR as low as 30 with albuminuria >300 mg/day.
In patients with an eGFR ≥60 needing additional glycemic control, the dose are often increased to 300 mg once daily.
Invokana is contraindicated in patients with an eGFR 300 mg/day.
DKD=diabetic kidney disease; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.
For more Prescription information: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf